HomeTWST • NASDAQ
add
Twist Bioscience Corp
Previous close
$41.66
Day range
$40.87 - $42.96
Year range
$23.07 - $60.90
Market cap
2.51B USD
Avg Volume
801.69K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 84.71M | 26.53% |
Operating expense | 74.28M | 9.52% |
Net income | -34.66M | 25.06% |
Net profit margin | -40.91 | 40.78% |
Earnings per share | -0.59 | 20.94% |
EBITDA | -31.99M | 10.40% |
Effective tax rate | 0.28% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 276.40M | -17.84% |
Total assets | 614.32M | -20.88% |
Total liabilities | 141.63M | -7.41% |
Total equity | 472.69M | — |
Shares outstanding | 59.36M | — |
Price to book | 5.19 | — |
Return on assets | -14.39% | — |
Return on capital | -15.86% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -34.66M | 25.06% |
Cash from operations | -15.32M | 26.00% |
Cash from investing | -1.28M | 42.81% |
Cash from financing | 3.63M | 720.59% |
Net change in cash | -12.90M | 42.79% |
Free cash flow | -6.51M | 34.40% |
About
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Founded
2013
Website
Employees
923
